PFKL

ATP-dependent 6-phosphofructokinase, liver type · P17858 · PFKL on Sugi Atlas →

0 patent compounds predicted against PFKL, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PFKL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes PHASE4COMPLETED
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. PHASE4COMPLETED
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes PHASE4COMPLETED
Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris PHASE4UNKNOWN
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus PHASE3COMPLETED
Ketohexokinase Inhibition in NAFLD PHASE2COMPLETED
Effect of Tulsi (Ocimum Sanctum) on Biochemical Parameters in Young Overweight and Obese Subjects PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Effect of Acute Fructose Load in Human nanCOMPLETED
Fructose and Glucose and TAS1R2 in Type 1 Diabetes nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging nanCOMPLETED
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting. nanNOT_YET_RECRUITING
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism nanUNKNOWN
Metabolic Determinants of Cardiac Function nanCOMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer nanUNKNOWN
Genetic-specific Effects of Fructose on Liver Lipogenesis nanCOMPLETED
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis nanWITHDRAWN
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway nanCOMPLETED
Echocardiographic Findings as Markers of Subclinical Cardiac Dysfunction in Patients With Non-Alcoholic Fatty Liver Disease nanUNKNOWN
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PFKL binder may also engage these)

ProteinNameSimilarity
P00511 1.000 P00511 →
Q60HD9 1.000 Q60HD9 →
PFKP ATP-dependent 6-phosphofructokinase, platelet type 1.000 landscape →
P12382 1.000 P12382 →
Q5R7V5 1.000 Q5R7V5 →
P47860 1.000 P47860 →
Q867C9 1.000 Q867C9 →
Q5RAG9 1.000 Q5RAG9 →
A1A4J1 1.000 A1A4J1 →
Q9HGZ1 0.999 Q9HGZ1 →
P47859 0.999 P47859 →
P30835 0.999 P30835 →
Q0IIG5 0.998 Q0IIG5 →
Q27778 0.998 Q27778 →
P52784 0.998 P52784 →
Q4W9B8 0.997 Q4W9B8 →
Q5R636 0.996 Q5R636 →
P47857 0.995 P47857 →
P08237 0.995 P08237 →
P47858 0.993 P47858 →
Q9WUA3 0.993 Q9WUA3 →
Q2HYU2 0.992 Q2HYU2 →
P78985 0.992 P78985 →
Q9FAF8 0.992 Q9FAF8 →
P52034 0.992 P52034 →
Q27665 0.991 Q27665 →
Q9FIK0 0.989 Q9FIK0 →
O42938 0.988 O42938 →
Q28479 0.987 Q28479 →
Q9TZL8 0.986 Q9TZL8 →